Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
130.00    -0.40 (-0.31%)
Bid:
129.60
Ask:
129.80
Spread: 0.20 (0.154%)
Market Cap: £316.44m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
9th Jun 20227:00 amRNSTransaction in Own Shares
8th Jun 20227:00 amRNSTransaction in Own Shares
7th Jun 20227:00 amRNSTransaction in Own Shares
6th Jun 20225:00 pmRNSTransaction in Own Shares
6th Jun 20227:05 amRNSAkili Adds Another Life Sciences Vet to C-Suite
6th Jun 20227:00 amRNSGLS Data at ADA: Metabolic Benefits & Gut Bacteria
1st Jun 202212:00 pmRNSPRTC to Present at Jefferies Healthcare Conference
1st Jun 20227:00 amRNSTotal Voting Rights
1st Jun 20227:00 amRNSTransaction in Own Shares
31st May 20227:00 amRNSTransaction in Own Shares
30th May 20227:00 amRNSTransaction in Own Shares
27th May 20227:00 amRNSTransaction in Own Shares
26th May 202212:05 pmRNSAkili & Roblox (NYSE:RBLX) Partner on EndeavorRx
26th May 20227:00 amRNSTransaction in Own Shares
25th May 20227:00 amRNSTransaction in Own Shares
24th May 20228:05 amRNSPRTC's Vedanta Presents Data at DDW Annual Meeting
24th May 20227:00 amRNSTransaction in Own Shares
23rd May 20227:00 amRNSTransaction in Own Shares
20th May 20227:00 amRNSTransaction in Own Shares
19th May 20227:00 amRNSPDMR Notification RSU Vesting
19th May 20227:00 amRNSTransaction in Own Shares
18th May 20227:00 amRNSTransaction in Own Shares
17th May 202212:00 pmRNSPRTC to Present at UBS Healthcare Conference
17th May 20227:00 amRNSTransaction in Own Shares
16th May 20222:30 pmRNSPRTC Presents LYT-100 Data at ATS Conference
16th May 20227:00 amRNSTransaction in Own Shares
13th May 20227:00 amRNSTransaction in Own Shares
12th May 20227:00 amRNSTransaction in Own Shares
11th May 20227:00 amRNSTransaction in Own Shares
10th May 20227:00 amRNSTransaction in Own Shares
9th May 20227:00 amRNSPRTC Share Buyback Programme Commences Purchases
5th May 20227:00 amRNSPRTC Announces Share Buyback Programme Up to $50M
4th May 202211:35 amRNSGelesis Presents GS200 Weight Loss Data at ECO
3rd May 20227:00 amRNSTotal Voting Rights
29th Apr 202211:05 amRNSGelesis Data: Therapeutic Shows Gut Health Benefit
26th Apr 20227:00 amRNSPRTC Final Results & Publication of Annual Report
13th Apr 20224:44 pmRNSPRTC's Vedanta Publishes VE303 Data
12th Apr 202212:05 pmRNSAkili Depression Data Published in AJP
12th Apr 20227:00 amRNSGlyph: 20x Oral Bioavailability of Buprenorphine
7th Apr 20227:00 amRNSNotice of Results
1st Apr 20227:00 amRNSTotal Voting Rights
24th Mar 20227:00 amRNSPRTC Appoints Merck Vet to BOD & Audit Committee
17th Mar 20221:05 pmRNSAkili Adds Gaming Vet as Chief Product Officer
16th Mar 202210:35 amRNSGelesis: Record-Breaking Plenity Prescriptions
8th Mar 202212:05 pmRNSAkili Named to World's Most Innovative Companies
18th Feb 20224:30 pmRNSHolding(s) in Company
17th Feb 202212:05 pmRNSAkili Data: Enhanced Brain Activity in Kids w/ADHD
15th Feb 20227:00 amRNSPRTC's Akili Files Registration Statement on S-4
10th Feb 202212:00 pmRNSPRTC to Present at Leerink Healthcare Conference
4th Feb 20227:00 amRNSPDMR DEALING - PURCHASE OF SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.